Periodic Reporting for period 1 - WILLEM: AI to Reduce Cardiovascular Diseases (WILLEM: AI to Reduce Cardiovascular Diseases)
Reporting period: 2022-11-01 to 2023-10-31
WILLEM is the first 100% automated cloud platform for electrocardiogram (ECG) analysis, designed to comprehensively identify and diagnose all types of arrhythmias and predict Cardiovascular Diseases (CVDs) behaviour at 6 months since its detection.
WILLEM communicates users and hospitals-in real time through a unique Cloud Platform, integrable with any other eHealth platform as part of the clinical workflow.
WILLEM provides the best prospective and labelled ECG database and, as a hardware-agnostic platform, it uses breakthrough Artificial Intelligence (AI) models to transform raw ECG signals from any monitoring device into a medical grade ECG report.
Today, WILLEM’s AI classifies 73 arrhythmias of the 288 known cardiac patterns, more than 90% of the cases, and it is the only solution that predicts Atrial Fibrillation. The goal is to classify every arrythmia present in human biology and to predict the 6 most prevalent heart diseases in an automatic and non-supervised way to reduce CVDs.
WILLEM communicates users and hospitals-in real time through a unique Cloud Platform, integrable with any other eHealth platform as part of the clinical workflow.
WILLEM provides the best prospective and labelled ECG database and, as a hardware-agnostic platform, it uses breakthrough Artificial Intelligence (AI) models to transform raw ECG signals from any monitoring device into a medical grade ECG report.
Today, WILLEM’s AI classifies 73 arrhythmias of the 288 known cardiac patterns, more than 90% of the cases, and it is the only solution that predicts Atrial Fibrillation. The goal is to classify every arrythmia present in human biology and to predict the 6 most prevalent heart diseases in an automatic and non-supervised way to reduce CVDs.
The project has started with the optimization of new WILLEM’s processes for cardiac arrhythmia classification, detection, and prediction, to improve WILLEM scope as a medical software according to CE marking Regulation (EU) and the FDA Clearance (US).
In parallel, IDOVEN has also been working in the implementation, integration and testing of a full cloud-based platform for non-supervised real-time SaaS ECG analysis. There has been started too, the personalization of API tools to seamlessly integrate WILLEM with third-party digital platforms.
Finally, dissemination and communication activities have beel also started, with the project presentation and marketing material elaboration and preliminary analysis for IPR protection and any other legal aspect related to project work.
In parallel, IDOVEN has also been working in the implementation, integration and testing of a full cloud-based platform for non-supervised real-time SaaS ECG analysis. There has been started too, the personalization of API tools to seamlessly integrate WILLEM with third-party digital platforms.
Finally, dissemination and communication activities have beel also started, with the project presentation and marketing material elaboration and preliminary analysis for IPR protection and any other legal aspect related to project work.
Thanks to the EIC Project, WILLEM will become a TRL9 SaaS with the highest arrhythmia identification, classification and prediction capabilities on the market with medical-grade accuracy. Its hardware-agnostic capabilities and its ability to integrate with other eHealth platforms, mainly through APIs, will enable hundreds of thousands of ECGs in a fully scalable way and without
the need for human supervision.
It is estimated that the average price of a 7-day ECG without human supervision and in real time (or less than 8 minutes) will be 10 euros, with an operating cost of 2 euros and 8 euros of margin.
The exponential growth of the project will come from massive ECG processing with very low operational costs.
If IDOVEN does not get the EIC Accelerator, our European digital Health market will be predictably dominated by US companies. China, with the largest number of patents on AI for ECG analysis, will bet on the European market and on the health data of European citizens.
the need for human supervision.
It is estimated that the average price of a 7-day ECG without human supervision and in real time (or less than 8 minutes) will be 10 euros, with an operating cost of 2 euros and 8 euros of margin.
The exponential growth of the project will come from massive ECG processing with very low operational costs.
If IDOVEN does not get the EIC Accelerator, our European digital Health market will be predictably dominated by US companies. China, with the largest number of patents on AI for ECG analysis, will bet on the European market and on the health data of European citizens.